Press Releases: GlaxoSmithKline

December 1, 2010

Biological Mimetics, Inc. Announces Research Agreement With GlaxoSmithKline

Collaboration to Focus on Biological Mimetics’ Proprietary  Immune Refocusing Technology

 

Frederick, MD – Biological Mimetics, Inc. (“BMI”), the developer of Immune Refocusing Technology, today announced a collaborative research relationship with GlaxoSmithKline (GSK). The joint effort will focus on the application of BMI’s Immune Refocusing Technology to the development of human vaccines. Additional details of the collaboration were not disclosed.

"We are extremely pleased to be working with GSK, a world leader in the development of human vaccines,” said Dr. Peter L. Nara, CEO of BMI. “This research program presents a significant opportunity for BMI to demonstrate the utility of Immune Refocusing Technology to the design of next generation therapeutic and prophylactic vaccines in areas of continuing unmet medical need.”

Morgan Joseph LLC acted as exclusive financial advisor to Biological Mimetics, Inc. with respect to the transaction.

About BMI - Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. As a result of BMI’s elucidation of “Deceptive Imprinting,” a mechanism of antigenic variation used by microbial pathogens and cancer cells to evade the host immune system, BMI developed “Immune Refocusing Technology” to circumvent such evasion mechanisms. Through the application of IRT, BMI strives to: (1) generate vaccines against pathogens for which no effective vaccine exists and (2) improve upon current strain-limited or serotype-limited protection of commercially available human and veterinary vaccines. IRT is able to alter the natural antigenicity and immunogenicity of targeted protein antigens making it a valuable tool to induce and select monoclonal antibodies. IRT can also be utilized to immune dampen therapeutic proteins and biologics to improve biological half-life and safety profiles.

BMI was founded in 1996 by scientists from the National Cancer Institute. The Company’s headquarters and R&D facilities are located in Frederick, Maryland.

For further information, please contact:

Dr. A. Ray Chaudhuri
Chief Financial Officer
301.620.7565 x 105
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Search Site

Virus Developments

BMI is developing an AIDS vaccine and applying its Immune Dampening and Refocusing Technology to the outer HIV envelope glycoprotein gp120/gp41, which is the main mediator of viral fusion and entry with host receptors CD4 and chemokine receptors CCR5 and/or CXCR4.

The Latest Technology

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of public health through the application of novel technologies for the development and commercialization of human and veterinary biologics to address a long list of hitherto intractable disease targets involving viruses, bacteria, parasites, and cancer.

Research & Development

pone_0020130_g003Globally, influenza is responsible for 250,000 to 500,000 deaths annually and is considered one of the most important respiratory pathogens of humans. In the majority of the past ten years, H3N2 has dominated in prevalence of infection and disease over H1N1, H2N2, and influenza B. In the United States alone, approximately 5–20% of the population contracts influenza illnesses leading to about 240,000 hospitalizations and 40,000 deaths with the majority due to H3N2. In addition to morbidity and mortality, influenza causes an annual economic impact in the range of $80B in this country alone. Click here to learn more .

Company News

blk triangleJune 2011: BMI announces collaborative research agreement with Crucell-BV for development of a universal influenza vaccine
blk triangleNov. 2010: BMI announces collaborative research agreement with GSK-Biologicals for development of an immune refocused vaccine for respiratory infection
blk triangleSept 2010: BMI is awarded a Qualifying Therapeutic Discovery Project Award
blk triangleJune 2010: BMI is awarded a Small Business Innovative Research Grant from the NIH for vaccine development
blk triangleNov. 2009: BMI is a prime contractor in the Fundamentals of Biology Program of DARPA/DSO for the study of modularity in biological systems
blk triangleMay 2008: BMI is awarded a subcontract for HIV vaccine development through the Henry M Jackson Institute for the Advancement of Military Medicine.
blk triangleJuly 2007: BMI is awarded a subcontract from DARPA through Rice University to study the evolution of pathogens
blk triangleJune 2007: BMI is awarded a subcontract from DARPA through VaxDesign (Orlando, Florida) to study immunogenicity of influenza